Global Duchenne Muscular Dystrophy Market – Industry Trends and Forecast to 2029

Duchenne Muscular Dystrophy Market Analysis and Size

The global duchenne muscular dystrophy market is expected to witness significant growth during the forecast period. Deletions in the gene for dystrophin within the body are the primary cause of duchenne muscular dystrophy. Presently, there are no cures for the disease and few of the treatments only provide limited relief. Although, major developments in gene therapy and stem cell therapies may offer more robust care for these patients. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the duchenne muscular dystrophy market in the forecast period 2022-2029. The expected CAGR of duchenne muscular dystrophy market is tend to be around 12.3% in the mentioned forecast period. The market was valued at USD 693.34 million in 2021, and it would grow upto USD 1753.82 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Duchenne Muscular Dystrophy Market Scope and Segmentation

Market Definition

Duchenne muscular dystrophy is an inherited disorder that primarily affects the muscle and is considered as an extreme form of muscular dystrophy. It is usually characterised by progressive muscular weakness that leads to wasting of muscle and atrophy of skeletal and heart muscles. There are numerous therapies and drugs to control DMD, though, there is yet no cure for duchenne muscular dystrophy. 

Global Duchenne Muscular Dystrophy Market Dynamics

Drivers

• Increased Use of Corticosteroids

Compared to the several other products, corticosteroids are possibly to emerge as the top-selling products during 2022-2029. By 2029 end, corticosteroids are expected to exceed US$ 9,000 million revenue. Numerous scientific research has found that compared to numerous products to treat duchenne muscular dystrophy, corticosteroids helps to improve muscle strength for up to two to five years, however, long-term benefit of corticosteroids is yet a vague concept.

• Increasing Clinical Research

Currently, more clinical trials are being conducted to assess potential treatments for Duchenne muscular dystrophy. The only approved pharmacological therapy for the management of DMD is an anti-inflammatory regimen based on corticosteroids. In the recent times, there has been a huge increase in the discovery and development of pharmaceutical drugs. Approximately all major companies are now focusing on R&D, possibly leaving a significant impact on the market in the upcoming years.

Opportunities

• Rising R&D and New Drug Approvals

The unmet needs of patients suffering from myelofibrosis are encouraging manufacturers to innovate new solutions. The rising investments in the research and development activities to develop a precise treatment for myelofibrosis is anticipated to boost the growth of the industry in the forecast period. The speedy technological advancements and ongoing clinical trials contribute to industry growth. Other factors such as improved healthcare sector, reimbursement policies, favourable government initiatives, busy lifestyle and changing dietary patterns are also resulting in the industry growth.   

• Varied New Treatments

Among the several treatment types, exon-skipping is holding a great demand. Internal deletions in the gene for dystrophin, a protein critical for preserving the integrity of muscle cell membranes, are the prime cause of Duchenne muscular dystrophy. To allow the remaining exons to come altogether, one therapeutic strategy is to mask an exon that is near to the location wherein the other exons are missing. For instance, in June 2022, Novartis announced, that the European Commission (EC) approved Tabrecta as a monotherapy for treating adults suffering from advanced non-small cell lung cancer (NSCLC) that has mutations that cause exon 14 (METex14) skipping and who require systemic therapy after receiving prior immunotherapy and/or platinum-based chemotherapy.

 Restraints/Challenges

• No cure for the Progressive Disorder

The most common challenge is that DMD is a progressive disorder, which means that the severity of the disease increases over time. Thus, early interventions in the Duchenne muscular dystrophy market, such as those that are used to treat other forms of muscular dystrophy, are not normally effective in treating DMD patients. Moreover, since DMD is a genetic condition, there is no known cure and no trustworthy way to slow or stop the progression of the disease. Thus, it boost the market growth.

• Lack of Awareness

The lack of awareness about the diseased condition and the unavailability of several awareness programs restrict the market growth.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth. The huge drug development and associated processes hamper the market's growth.

This global duchenne muscular dystrophy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global duchenne muscular dystrophy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In September 2022, University of Portsmouth, I-STEM, CNRS, Maj Institute of Pharmacology of the Polish Academy of Sciences, and AFM in France found in a study that  DMD begins much earlier in cells destined to become muscle fibers, known as myoblasts.
• In September 2022, it was found that Eteplirsen is effective in delaying pulmonary reduction in patients with DMD
• In September 2022, researchers from Johns Hopkins Medicine found that experimental drug first developed to treat patients suffering from kidney disease extends survival rate and improves muscle function in mice, genetically engineered to develop a severe form of Duchenne muscular dystrophy (DMD).

Global Duchenne Muscular Dystrophy Market Scope

The global duchenne muscular dystrophy market is segmented on the basis of therapy, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy

• Mutation Suppression
• Exon Skipping Approach

Treatment Type

• Molecular-based Therapies
•  Steroid Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Duchenne Muscular Dystrophy Market Regional Analysis/Insights

The global duchenne muscular dystrophy market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global duchenne muscular dystrophy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for global duchenne muscular dystrophy market throughout the forecasted period due to the increased awareness about the diseases and rapidly disposable income.

North America dominates the market due to the increase prevalence of myelofibrosis (MF), high demand of targeted therapies and advanced healthcare facilities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Duchenne Muscular Dystrophy Market Share Analysis

The global duchenne muscular dystrophy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global duchenne muscular dystrophy market.

Key players operating in the global duchenne muscular dystrophy market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (U.K.)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol Myers Squibb Company (U.S.)
• GSK Plc. (U.K.)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd (India)
• Boehringer Ingelheim International Gmbh (Germany)
• Sanofi (France)
• Sarepta Therapeutics, Inc (U.K.)
• FibroGen, Inc. (U.S.)

SKU-54418